Debra Durso-Bumpus Sells 333 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Debra Durso-Bumpus sold 333 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $111.15, for a total transaction of $37,012.95. Following the sale, the insider now directly owns 43,763 shares in the company, valued at approximately $4,864,257.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Debra Durso-Bumpus also recently made the following trade(s):

• On Friday, June 21st, Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock. The stock was sold at an average price of $104.19, for a total transaction of $7,713,602.46.

Blueprint Medicines Trading Down 1.2 %

Shares of Blueprint Medicines stock opened at $109.03 on Friday. The company has a fifty day simple moving average of $104.71 and a 200-day simple moving average of $93.30. Blueprint Medicines Co. has a 12-month low of $43.89 and a 12-month high of $111.89. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of -22.67 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.32. The company had revenue of $96.12 million during the quarter, compared to analysts’ expectations of $82.58 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. On average, equities analysts forecast that Blueprint Medicines Co. will post -5.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds have recently made changes to their positions in BPMC. Readystate Asset Management LP acquired a new stake in Blueprint Medicines during the 4th quarter worth approximately $3,692,000. Vanguard Group Inc. lifted its holdings in shares of Blueprint Medicines by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after purchasing an additional 147,827 shares during the period. American Century Companies Inc. grew its position in Blueprint Medicines by 5.2% in the 3rd quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock valued at $33,696,000 after buying an additional 33,243 shares during the last quarter. Axiom Investors LLC DE acquired a new position in Blueprint Medicines in the 4th quarter valued at $2,212,000. Finally, Diversified Trust Co raised its holdings in Blueprint Medicines by 2.9% during the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock worth $563,000 after purchasing an additional 318 shares in the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines in a research note on Friday, June 28th. Wedbush reaffirmed an “outperform” rating and issued a $110.00 price target on shares of Blueprint Medicines in a research report on Friday, April 26th. Stephens began coverage on Blueprint Medicines in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $140.00 price objective for the company. HC Wainwright boosted their price objective on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Finally, SVB Leerink raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and raised their target price for the company from $50.00 to $97.00 in a report on Monday, May 6th. One analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average price target of $110.20.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.